Form 4: Pfizer Director Shantanu Narayen Reports Acquisition of Phantom Stock Units

Pfizer Inc. Director Shantanu Narayen reported the acquisition of 2,062.706 phantom stock units as deferred compensation, valued at $24.24 per unit, bringing his total beneficial ownership of derivative securities to 173,181.749 units.

Summary

• Shantanu Narayen, a Director at Pfizer Inc. (PFE), acquired 2,062.706 phantom stock units.
• The transaction date for this acquisition was June 30, 2025.
• Each phantom stock unit represents one phantom share of common stock and was valued at $24.24.
• These units are part of deferred director's compensation, including dividend equivalents.
• The units will be settled in cash or common stock at the director's election upon retirement from the Board of Directors.
• Following this transaction, Shantanu Narayen beneficially owns a total of 173,181.749 derivative securities (phantom stock units).

Sentiment

Score: 5

Explanation: The document is a routine Form 4 filing detailing director compensation, which is neutral in sentiment as it reflects standard corporate governance and compensation practices without indicating any significant positive or negative operational or financial developments.

Positives

• Demonstrates ongoing compensation structure for board members, aligning director interests with shareholder value through equity-linked incentives.
• The acquisition of phantom stock units is a standard component of director compensation, reflecting a routine operational aspect of corporate governance.

Negatives

• No negative information is disclosed in this routine Form 4 filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The phantom stock units represent deferred compensation that will be settled in cash or common stock at the director's election following retirement from the Board of Directors.

Management Comments

• No direct quotes or paraphrased statements from company management are included in this Form 4 filing.

Industry Context

This Form 4 filing details a routine director compensation event for Pfizer Inc., which is common practice across publicly traded companies in the pharmaceutical and broader industries. Such compensation structures, often involving equity-linked instruments like phantom stock units, are designed to align the interests of board members with long-term shareholder value, a prevalent trend in corporate governance.

Comparison to Industry Standards

• The use of phantom stock units as a form of deferred director compensation is a widely adopted practice among large-cap pharmaceutical companies and other global corporations.
• Companies like Johnson & Johnson (JNJ), Merck & Co. (MRK), and Eli Lilly and Company (LLY) also utilize various forms of equity-based compensation for their non-employee directors to incentivize long-term commitment and performance.
• The specific value and number of units are commensurate with compensation packages for directors at companies of similar size and market capitalization within the healthcare sector.

Stakeholder Impact

• Shareholders: The compensation structure aligns director interests with long-term shareholder value, as the units are tied to the company's stock performance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Settlement of the phantom stock units in cash or common stock upon the reporting person's retirement from the Board of Directors.

Key Dates

Keywords

Pfizer, PFE, Shantanu Narayen, Form 4, SEC filing, Insider transaction, Director compensation, Phantom stock units, Equity compensation, Deferred compensation